Alpine Immune Sciences Inc Stock News

Analysts forecast that Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will report sales of $8.26 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Alpine Immune Sciences earnings. The lowest sales estimate is $5.29 million and the highest is $10.00 million. Alpine Immune Sciences reported sales of $5.64 million in the []

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Present ALPN-303 Data at American College of Rheumatology Convergence 2021 Annual Meeting

Alpine Immune Sciences, Inc. (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory

Alpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q2 2021 Results - Earnings Call Transcript

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -58.62% and 9.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the s

Shares of Alpine Immune Sciences (NASDAQ:ALPN) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 13.21% year over year to ($0.46), w

Celldex: Powerful Medicines To Yield Further Upsides

Alpine Immune Sciences Inc (NASDAQ: ALPN) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK).  This collaboration will evaluate the safety and e

Biogen isn't the only company whose shares should benefit from a breakthrough drug.

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces ALPN-202 Clinical Data Presented at the 2021 ASCO Virtual Annual Meeting

Alpine Immune Sciences Inc (NASDAQ: ALPN) has presented the preclinical data from its ALPN-303 program at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumat

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting

Alpine Immune Sciences is a fundamental stock that is ideal for you to build a core long-term position. The company recently released preliminary NEON-1 data for the upcoming 2021 ASCO.